Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
scopolamine + thyrotropin-releasing hormone
- Development stage
- Preclinical
- Modality
- Small Molecules, Peptides
- Administration
- Intravenous
01
Overview
A combination of scopolamine (an anticholinergic agent) and thyrotropin-releasing hormone (TRH, a tripeptide neuromodulator) used primarily in research settings to study cognitive function and cholinergic system interactions. In young subjects, TRH has been shown to attenuate scopolamine-induced memory impairment, while in older subjects and Alzheimer's patients, the interaction produces different effects. Scopolamine appears to attenuate the pressor (blood pressure raising) effect of TRH.
02
Targets
TRHR (Thyrotropin-releasing hormone receptor)mAChR (Muscarinic acetylcholine receptors)
Beyond the preview
Go deeper on scopolamine + thyrotropin-releasing hormone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on scopolamine + thyrotropin-releasing hormone.